Immune resistance orchestrated by the tumor microenvironment.
about
Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parametersNew Strategies for the Treatment of Solid Tumors with CAR-T CellsTexosome-based drug delivery system for cancer therapy: from past to presentThe Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor MicroenvironmentCAR T cells for solid tumors: armed and ready to go?Combining radiation and immunotherapy: a new systemic therapy for solid tumors?The STING pathway and the T cell-inflamed tumor microenvironmentCombining radiotherapy and cancer immunotherapy: a paradigm shiftThe optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translationCurrent translational and clinical practices in hematopoietic cell and gene therapyRecent advances in therapeutic cancer vaccinesCancer immunotherapyB7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infectionsSpatial and functional heterogeneities shape collective behavior of tumor-immune networksDistinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cellsImmunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor MicroenvironmentImmune evasion pathways and the design of dendritic cell-based cancer vaccinesEnhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case studyThe roles of Galectin-3 in autoimmunity and tumor progressionAn Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer CellsTrafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cellsChemokine expression in melanoma metastases associated with CD8+ T-cell recruitmentEmerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in OncologyMatrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors.Rapid maturation of effector T cells in tumors, but not lymphoid organs, during tumor regression.Tunable chemokine production by antigen presenting dendritic cells in response to changes in regulatory T cell frequency in mouse reactive lymph nodes.Immunotherapy in acute leukemiaDisruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity.RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expressionHeterogeneity of aberrant immunoglobulin expression in cancer cells.Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulationNew insights into the role of EMT in tumor immune escape.Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.Differences in TCR-Vβ repertoire and effector phenotype between tumor infiltrating lymphocytes and peripheral blood lymphocytes increase with age.Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumorsTumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedIL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cellsIn silico models of cancerPrevention is better than cure: the case for clinical trials of therapeutic cancer vaccines in the prophylactic setting.Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.
P2860
Q24615872-AFC51BF0-B896-49C5-9995-C67CC2186ABAQ26748500-291666FA-87DC-4E9F-BCCB-37E8D6404B29Q26778833-7CC9AFC3-323D-42B7-BAC5-7E611AD198DFQ26796305-B4803E5E-9447-4DD6-B9D0-ECD5F44DCC81Q26825489-11AED336-D8A1-48AD-9B8A-E6E09EF14CC6Q26991721-62D4D067-FDF0-45A1-AA3E-B5ECD83B7586Q27008371-6BE00B6F-6627-4F3B-9D22-164DDA614544Q27021428-6B6E0E11-73E3-4612-8B56-24BA68227D8BQ27024106-7038D7A9-8EC2-47D8-8F9E-DE75D39BCDDEQ27024456-2F209432-781A-4B30-AA75-0CF74A5BBA1CQ27025266-5802BBA0-04C2-47A7-BDED-05BA5FC46A86Q27026870-3F529955-3846-4EE9-83EA-8EED8DABAF5BQ27317015-489726D8-23BB-4D7A-901F-6B6B1AA1CEBAQ27319519-3F7101E9-C736-49A1-87BB-15F04C4683C7Q27438176-C0598849-4E23-4D8B-A0E2-38C3D50990ADQ28071935-AF5CC287-CC99-4E3D-A75A-17C530AA06D3Q28076556-E3BB4BCA-523B-4D20-B114-F2EF145E2626Q28084489-77F308A3-6378-496D-9413-71FD1C7CD18FQ28261890-BB4CD529-4280-44D3-A500-87458705D526Q28547142-7DC6600B-C9FA-46D8-B7ED-691B251D87B0Q28732041-09D0A9B3-D58B-40AD-A6D2-9D0737088285Q30415355-A734A3F6-0163-46FF-BABC-5696F7869494Q30438965-9F5865DA-00CD-420B-95B0-8CF1A355CB4FQ30505678-BC265DEA-65E3-4A37-91C0-E2E3C1417087Q33296983-FF7ECA0A-9919-48F7-97F1-9EDB18326735Q33515288-599D56A2-9672-4D0B-8000-C516F3216A5FQ33731552-FBC3114E-0651-4415-ABBD-93D5A9D57A92Q33772507-A8FD18F1-43B2-48ED-8C4D-45B1A0B53771Q33816240-54F21521-4FEA-4046-A592-2FBC84242E8EQ33827480-B9B6F8C2-C8C5-4D39-A8A7-574D0CE46892Q33848077-A90EEA3C-5887-418F-8466-E54DD89A959DQ33869781-D37CA3CA-22AC-4BF1-BEC4-AF7A1D15BF7DQ33889105-4D663E7C-7853-4C1C-8130-20D6CB9E903DQ33895977-3428EEB0-7A3F-4412-965F-DE4ADCDDF689Q34052580-A969198E-AC54-4DA0-91C4-50B0D7AB662FQ34080914-0F9C7EBC-C692-42B7-BBAD-885031500BF2Q34095907-CC0A443D-B005-4123-91AB-89C2BE7F9264Q34137584-F1A6B450-5309-4890-B29C-4B73AB8C01FAQ34248816-01952D6F-ABD8-4DC6-80C2-1AE184B12A4DQ34508125-C4C92AA5-37C2-499E-A8A0-BD580138B262
P2860
Immune resistance orchestrated by the tumor microenvironment.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Immune resistance orchestrated by the tumor microenvironment.
@ast
Immune resistance orchestrated by the tumor microenvironment.
@en
type
label
Immune resistance orchestrated by the tumor microenvironment.
@ast
Immune resistance orchestrated by the tumor microenvironment.
@en
prefLabel
Immune resistance orchestrated by the tumor microenvironment.
@ast
Immune resistance orchestrated by the tumor microenvironment.
@en
P2093
P2860
P1476
Immune resistance orchestrated by the tumor microenvironment.
@en
P2093
Aalok Kacha
Christian Blank
Helena Harlin
Justin Kline
Thomas F Gajewski
P2860
P304
P356
10.1111/J.1600-065X.2006.00442.X
P577
2006-10-01T00:00:00Z